BioCentury | Oct 19, 2020
Finance

How Nimbus’ focus on internal pipeline could point to long-awaited exit

...sequence b (CBLB) Werner syndrome RecQ like helicase (WRN) Mitogen-activated protein kinase kinase kinase kinase 1 (HPK1) (MAP4K1) Tyrosine...
BioCentury | Jan 14, 2020
Company News

Treadwell emerges with two clinical cancer compounds, $27M seed from Tio

...4; TTK (MPS1) - TTK protein kinase Sandi Wong, Assistant Editor University Health Network TTK protein kinase (TTK) (MPS1) Mitogen-activated protein kinase kinase kinase kinase 1 (HPK1) (MAP4K1) Treadwell...
BioCentury | Jul 9, 2019
Company News

July 9 Company Quick Takes: Celgene, Nimbus expand deal; plus Gilead-Lyndra, Darzalex and more

...VPD-107 tislelizumab (BGB-A317) Alector Inc. Altimmune Inc. BeiGene Ltd. Celgene Corp. Gilead Sciences Inc. Johnson & Johnson Lyndra Therapeutics Inc. Nimbus Therapeutics LLC WinterLight Labs Inc. Mitogen-activated protein kinase kinase kinase kinase 1 (HPK1) (MAP4K1) Programmed...
BioCentury | Nov 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: October 2018

New Therapeutic Targets and Biomarkers: October 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October. Therapeutic targets are defined as any protein, gene or other molecule...
BioCentury | Oct 11, 2018
Distillery Therapeutics

Cancer; infectious disease

...2, 2018 doi:10.1016/j.celrep.2018.09.012 CONTACT: Ira Mellman, Genentech Inc., South San Francisco, Calif. email: mellman.ira@gene.com Sandi Wong Genentech Inc. Mitogen-activated protein kinase kinase kinase kinase 1 (HPK1) (MAP4K1) Programmed...
BioCentury | Oct 3, 2018
Preclinical News

Kinase identified as new cancer immunotherapy target

Genentech Inc. scientists identified a kinase as a new cancer immunotherapy target in a Cell Reports study led by VP of Cancer Immunology Ira Mellman. The results suggest that inactivation of the kinase enhances T...
Items per page:
1 - 6 of 6